Veracyte, Inc. (NASDAQ: VCYT) announced on September 30, 2025 that the BALANCE trial, a prospective, randomized study (NCT03371719), has validated the PAM50 molecular signature as a predictor of benefit from apalutamide added to salvage radiation therapy in men with recurrent, non‑metastatic prostate cancer.
The trial enrolled 295 men, of whom 127 had luminal B tumors as defined by the PAM50 signature. Among these luminal B patients, 72% of those treated with apalutamide experienced no biochemical failure compared with 54% of placebo recipients (hazard ratio 0.45, 80% CI 0.29‑0.68, p = 0.0062). No difference was observed in the non‑luminal B subgroup (70% vs 71%).
This first prospective validation demonstrates that the PAM50 biomarker can identify patients who will derive meaningful benefit from hormone therapy, providing a new tool for clinicians to personalize treatment. The data support broader adoption of Veracyte’s Decipher platform and may accelerate reimbursement and guideline inclusion, positioning the company for increased market penetration and revenue growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.